Arrowstreet Capital
AUTL

Arrowstreet Capital’s Autolus Therapeutics AUTL Stock Holding History

Arrowstreet Capital’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-273,929
Closed -$1.75M – 1523
2024
Q1 		$1.75M Buy
273,929
+252,601
+1,184% +$1.58M ﹤0.01% 1174
2023
Q4 		$137K Buy
+21,328
New +$81.3K ﹤0.01% 1361

Other funds holding AUTL

SP
Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Arrowstreet Capital's AUTL Position: Q2 2024 in Review

Arrowstreet Capital sold out of Autolus Therapeutics (AUTL) in Q2 2024, closing a stake of 273,929 shares — an estimated $1.75M sold.

Arrowstreet Capital first reported a position in AUTL in Q4 2023 and held it in 2 quarters. The position peaked at $1.75M in Q1 2024. 111 funds tracked by Wall St. Rank hold AUTL as of Q2 2024.

  • Arrowstreet Capital reported no remaining Autolus Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Arrowstreet Capital sold 273,929 Autolus Therapeutics shares in Q2 2024, an estimated $1.75M.
  • Arrowstreet Capital first reported a position in Autolus Therapeutics in Q4 2023 and held it in 2 quarters.
  • Arrowstreet Capital's Autolus Therapeutics position peaked at $1.75M in Q1 2024.
  • 111 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q2 2024.

Based on Arrowstreet Capital's 13F filing for Q2 2024, filed 14 Aug 2024.